中安科股份有限公司 关于2023年股票期权与限制性股票激励计划2025年 第四季度自主行权结果暨股份变动公告

Core Viewpoint - The company has implemented a stock option and restricted stock incentive plan, with significant participation and completion of stock transfers in the second exercise period, indicating strong engagement from the incentive recipients [2][11]. Summary by Sections Incentive Plan Overview - The total number of stock options exercised in the second exercise period is 1,170,480 shares, representing 60.96% of the total options available for exercise [2]. - As of the end of the fourth quarter of 2025, a cumulative total of 1,883,021 shares have been exercised and registered, accounting for 98.07% of the total options available for the second exercise period [2]. Decision-Making Process and Disclosure - On March 17, 2023, the company’s board approved the incentive plan and related proposals, with independent directors providing clear consent [3]. - The company publicly disclosed the names and positions of the incentive recipients from March 18 to March 27, 2023, with no objections received during this period [3]. Stock Option Grant and Registration - On April 3, 2023, the company held a shareholder meeting to approve the grant of stock options and restricted stocks to 148 eligible recipients, totaling 65.5 million options and stocks [5]. - The stock options were registered on June 1, 2023, with 10.05 million options registered for 42 individuals [5]. Stock Buyback and Cancellation - On December 1, 2023, the company approved the buyback and cancellation of 1,130,000 restricted stocks from two former incentive recipients [6]. - The company continued to manage stock buybacks and cancellations throughout 2024, including the cancellation of options and stocks from individuals who left the company [9][12]. Exercise Results and Financial Impact - In the fourth quarter of 2024, 2,479,460 shares were exercised, representing 99.23% of the first exercise period options [11]. - The company reported that the exercise of stock options and the issuance of new shares would not have a significant impact on its financial status or operational results [18]. Fund Utilization - The funds raised from the exercise of stock options in the fourth quarter of 2025 amounted to 2,340,960 RMB, which will be used to supplement the company's working capital [17].